Is ABVX.PA undervalued or overvalued?
As of 2025-03-19, the Intrinsic Value of Abivax SA (ABVX.PA) is -14.00 EUR. This ABVX.PA valuation is based on the model Peter Lynch Fair Value. With the current market price of 5.78 EUR, the upside of Abivax SA is -342.16%. This means that ABVX.PA is overvalued by 342.16%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -14.00 - -14.00 | -14.00 | -342.16% |
| P/E | (30.85) - (26.09) | (30.09) | -620.6% |
| DDM - Stable | (28.99) - (122.74) | (75.86) | -1412.5% |
| DDM - Multi | (19.36) - (64.48) | (29.87) | -616.7% |
| Market Cap (mil) | 366.34 |
| Beta | 1.05 |
| Outstanding shares (mil) | 63.38 |
| Enterprise Value (mil) | 240.74 |
| Market risk premium | 5.82% |
| Cost of Equity | 8.41% |
| Cost of Debt | 5.00% |
| WACC | 7.89% |